Company

Spero

Spero Therapeutics

SPRO pharma USA

Quick answer

Spero is a pharma company (SPRO) headquartered in CAMBRIDGE, MA, USA with 20 tracked pipeline programs.

Pipeline (20)

TBP-PI-HBr

Urinary Tract Infection

Phase 3 · small_molecule · completed

1 trials project

TBPM-PI-HBr

Complicated Urinary Tract Infection

Phase 3 · small_molecule · completed

1 trials project

Placebo

Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Phase 2 · small_molecule · completed

1 trials project

SPR720

Mycobacterium Avium Complex

Phase 2 · small_molecule · terminated

1 trials project

SPR206

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

SPR206

Renal Impairment

Phase 1 · small_molecule · completed

1 trials project

SPR720

Healthy Volunteer

Phase 1 · small_molecule · completed

1 trials project

SPR720

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

SPR720 for SAD

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

SPR741

Healthy Volunteers

Phase 1 · small_molecule · completed

2 trials project

SPR994

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

TBP-PI-HBr

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

TBP-PI-HBr

Healthy Participants

Phase 1 · small_molecule · completed

1 trials project

TBPM-PI-HBr

Healthy Volunteers

Phase 1 · small_molecule · completed

3 trials project

Tebipenem Pivoxil Hydrobromide

Diabetes

Phase 1 · small_molecule · completed

1 trials project

Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo

TQT Study

Phase 1 · small_molecule · completed

1 trials project

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)

Renal Impairment

Phase 1 · small_molecule · completed

1 trials project

Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

Tebipenem tablet form

Relative Bioavailability

Phase 1 · small_molecule · completed

Patents (8)

US 12428395

Heterocyclic compounds as kinase inhibitor and uses thereof

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12291548

Compounds, compositions, and methods for the treatment of disease

Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12226403

Tebipenem pivoxil immediate and modified release oral dosage forms

Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12146004

Polymyxin compounds and uses thereof

Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12098155

Tebipenem pivoxil crystalline forms, compositions including the same, methods of

Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12048691

High dosage tebipenem pivoxil tablet formulation

Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11718621

Tebipenem pivoxil crystalline forms, compositions including the same, methods of

Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

US 11459357

Polymyxin compounds

Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026